Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

Clinical trial NCT06508931 · RECRUITING

Trial details

NCT number: NCT06508931
Sponsor: Miltenyi Biomedicine GmbH
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

B-Cell Neoplasm

Start date: 2025-08-04
Primary completion: 2029-12-31
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.